Literature DB >> 16416455

Conditionally replicative adenoviral vectors for malignant glioma.

Adam M Sonabend1, Ilya V Ulasov, Maciej S Lesniak.   

Abstract

High-grade gliomas constitute an important challenge to modern medicine, and although great effort has been made to prolong patient survival, the prognosis for this disease remains poor. Due to recent discoveries in the molecular basis of gliomas, gene therapy is becoming a promising alternative. In this review, we discuss the use of conditionally replicative adenoviral vectors (CRAd) and their applications in neuro-oncology. Such vectors, when rendered conditionally replicative via transductional and transcriptional modifications, offer great promise for patients with malignant brain tumours. We review data from preclinical and clinical studies utilising such vectors and discuss the limitations and future perspectives of CRAd oncolytic therapy for malignant glioma. 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh：

Year:  2006        PMID： 16416455     DOI： 10.1002/rmv.490

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN： 1052-9276            Impact factor:   6.989


  8 in total

1.  Targeting lung cancer using an infectivity enhanced CXCR4-CRAd.

Authors:  Zeng B Zhu; Angel A Rivera; Sharmila K Makhija; Baogen Lu; Minghui Wang; Miiru Izumi; Robert J Cerfolio; Mariam A Stoff-Khalili; Fen Zhou; Koichi Takayama; Gene P Siegal; David T Curiel
Journal:  Lung Cancer       Date:  2006-11-17       Impact factor: 5.705

2.  A novel adenoviral vector labeled with superparamagnetic iron oxide nanoparticles for real-time tracking of viral delivery.

Authors:  Jonathan Yun; Adam M Sonabend; Ilya V Ulasov; Dong-Hyun Kim; Elena A Rozhkova; Valentyn Novosad; Stephen Dashnaw; Truman Brown; Peter Canoll; Jeffrey N Bruce; Maciej S Lesniak
Journal:  J Clin Neurosci       Date:  2012-04-18       Impact factor: 1.961

Review 3.  Advances in oncolytic virus therapy for glioma.

Authors:  Amy Haseley; Christopher Alvarez-Breckenridge; Abhik Ray Chaudhury; Balveen Kaur
Journal:  Recent Pat CNS Drug Discov       Date:  2009-01

Review 4.  Adenoviral virotherapy for malignant brain tumors.

Authors:  Suvobroto Nandi; Maciej S Lesniak
Journal:  Expert Opin Biol Ther       Date:  2009-06       Impact factor: 4.388

5.  Truncating the i-leader open reading frame enhances release of human adenovirus type 5 in glioma cells.

Authors:  Sanne K van den Hengel; Jeroen de Vrij; Taco G Uil; Martine L Lamfers; Peter Ae Sillevis Smitt; Rob C Hoeben
Journal:  Virol J       Date:  2011-04-11       Impact factor: 4.099

6.  Tamoxifen improves cytopathic effect of oncolytic adenovirus in primary glioblastoma cells mediated through autophagy.

Authors:  Ilya V Ulasov; Nameeta Shah; Natalya V Kaverina; Hwahyang Lee; Biaoyang Lin; Andre Lieber; Zaira G Kadagidze; Jae-Guen Yoon; Brett Schroeder; Parvinder Hothi; Dhimankrishna Ghosh; Anatoly Y Baryshnikov; Charles S Cobbs
Journal:  Oncotarget       Date:  2015-02-28

7.  Evaluation of adenovirus capsid labeling versus transgene expression.

Authors:  Jing Li; Aiman Fatima; Svetlana Komarova; Hideyo Ugai; Priyanka Uprety; Justin C Roth; Minghui Wang; Robert A Oster; David T Curiel; Qiana L Matthews
Journal:  Virol J       Date:  2010-01-26       Impact factor: 4.099

8.  Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.

Authors:  I V Ulasov; A M Sonabend; S Nandi; A Khramtsov; Y Han; M S Lesniak
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.